Alzheimer’s affects over seven million Americans—a number expected to double by 2050. New FDA-approved drugs and early-detection blood tests give families hope, but government red tape still stands in the way. The Market Institute believes patients and doctors—not bureaucrats—should decide when to use lifesaving innovations. Empowering access to modern treatments isn’t just good policy—it’s the compassionate choice.
The healthcare system is often described as broken, but as Charles Sauer explained during a recent event hosted by the Mises Institute, the solutions already exist. The challenge is not creating better models of care—it’s Read more…
A bipartisan effort in Congress seeks to reinforce First Amendment protections by preventing federal officials from pressuring private companies to censor lawful speech. In a new RealClearMarkets column, Market Institute Senior Fellow Norm Singleton examines Read more…
A new opinion piece by Market Institute President Charles Sauer in RealClearMarkets argues that policymakers should resist efforts to ban personalized pricing, warning that government intervention would undermine consumer choice and market efficiency. As retailers Read more…
A newly published paper in The Milbank Quarterly adds to the growing body of evidence that the federal 340B Drug Pricing Program has strayed far from its original purpose, strengthening the case for meaningful congressional Read more…
A new RealClearHealth op-ed by Dr. Craig Wax argues that if Congress is serious about reducing healthcare costs and increasing competition, lawmakers must reform one of the federal government’s biggest distortions: Medicare’s unequal payment system. Read more…
The American Innovation and Choice Online Act (AICOA) is back before Congress, and in a new RealClearMarkets op-ed, Market Institute Senior Fellow Norm Singleton argues lawmakers should finally let the legislation die. Comparing the bill Read more…
6151 Fuller Court #8
Alexandria, VA 22310
The Market Institute
info@marketinstitute.org